A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

To join this study, you must be an adult aged 18 or older and have a confirmed diagnosis of Sjögren's disease for at least six months. Your Sjögren's disease needs to be active and considered moderate to severe by the doctors. You'll also need to have certain blood test results within a healthy range, as these tests help ensure it's safe for you to take part and that your body is likely to respond well to the medicine.

There are also some reasons why you might not be able to join. For example, if you have another autoimmune disease like rheumatoid arthritis or lupus, or if you've recently had certain serious infections like Hepatitis B, C, HIV, or active tuberculosis. People who have had a stroke, seizures, or certain other brain or nerve conditions, or those with very severe kidney disease, would also not be able to take part. This is because these conditions could either make the study medicine unsafe for you or make it harder for the researchers to understand the study results accurately.

If you decide to take part in this study, you will receive the study medicine, CLN-978, as an injection under your skin. This isn't a 'blinded' study, which means you and your doctors will know you are receiving the active medicine. You'll have regular visits to the clinic so the medical team can monitor your health carefully, perform physical exams, and take blood and urine samples. They will also ask you questions about your symptoms and how you're feeling. The study team will explain how long you'll be involved and what each visit will include. All these assessments help the researchers understand how safe the medicine is and if it's having any effect on your Sjögren's disease.